Clinical trial

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

NCT06393816

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-06-13

PhasePHASE2

Study timeline

Study start (actual)2024-06-13Date precision: day

Registry last updated2024-08-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Large Cell Neuroendocrine Carcinoma of the Lungunresolved

Interventions

Durvalumab with etoposide and Carboplatin/CisplatinDRUG

Sponsors & collaborators

Centre Leon Berardlead sponsor

Groupe Francais De Pneumo-Cancerologiecollaborator

Mapped research locations

ParisFrance2 StrasbourgFrance2 ToulouseFrance1 MarseilleFrance1 LyonFrance1 LilleFrance1 RennesFrance1 NiceFrance1 CaenFrance1 Clermont-FerrandFrance1 GrenobleFrance1 BrestFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06393816 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.